NVIDIA introduces NV-Tesseract, a model family transforming time-series data analysis, enhancing anomaly detection, forecasting, and classification across industries including finance and healthcare.

According to @zenmev, repeated staking with ZenMEV is gaining popularity due to the platform's MEV-based returns, which are attracting traders seeking optimized crypto yield strategies. MEV, or Miner ...

According to Mihir (@RhythmicAnalyst) on Twitter, Bitcoin (BTC) is currently testing a critical resistance zone that has not only defined Cycle #5 but also represents a major long-term trendline since ...

According to Mihir (@RhythmicAnalyst) on Twitter, BTC dominance has executed a textbook move by flipping a key resistance level into new support, as detailed in the initial post of his thread (source: ...

According to Edward Dowd, the $SPX stock market is influenced by earnings growth and multiple expansion, but recent policy actions, such as tariffs and price controls ...

According to @EmberCN, prominent trader @qwatio has opened a high-leverage short position in Bitcoin and Lido DAO on Hyperliquid. The trader used $2.683 million USDC as margin for a 40x short on 888.8 ...

According to AltcoinGordon, there is growing anticipation for a new alt season in 2025, with the potential for significant gains across major altcoins. The tweet highlights that traders who stay ...

根据AltcoinGordon在推特上的分析，2025年加密货币市场的高回报机会往往伴随着更高的难度和波动性，交易者需要克服各种挑战才能取得成功。AltcoinGordon建议投资者应关注关键市场趋势与价格信号 ...

According to Evan (@StockMKTNewz) on Twitter, Tesla's TSLA free cash flow has shown significant year-over-year improvement since 2015, transitioning from negative to positive territory in recent years ...

According to StockMKTNewz, President Trump announced he will sign an executive order to reduce prescription drug and pharmaceutical prices by 30% to 80% almost immediately (source: StockMKTNewz, May ...

2025年被誉为加密货币的转折之年，市场情绪异常乐观。5月11日，知名加密货币影响者Crypto Rover在社交媒体上发文称“2025是加密货币之年”，并预测“今年将诞生百万富翁”。虽然这是个人观点 ...

According to Edward Dowd, recent developments are unfavorable for pharmaceutical benefit management companies such as $CVS, $CI, $HUM, and $ESRX, as highlighted in ...